Articles Vol. 67 No. 4 25/04/2026

SYTEMATIC REVIEW OF THE SAFETY AND EFFICACY OF PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME

Pham Huy Tuan Kiet1,2, Nguyen Thi Thu Huong1,2, Le Hong Minh3,4, Trinh Thi Thanh Mai1,2
1 Institute of Preventive Medicine and Public Health Training, Hanoi Medical University
2 Viện Đào tạo Y học dự phòng và Y tế công cộng, trường Đại học Y Hà Nội
3 Center for Health Economics Research and Evaluation
4 Trung tâm Nghiên cứu và Đánh giá kinh tế y tế
DOI: 10.52163/yhc.v67i4.4911
14 Views
6 Downloads
Keywords
Prasugrel; Safety; Efficacy; Acute Coronary Syndrome (ACS)
Abstract

Background: In the treatment of Acute Coronary Syndrome (ACS), Prasugrel is recommended, alongside aspirin, for adult patients undergoing percutaneous coronary intervention (PCI) to prevent thrombotic events. Objective: This study aims to conduct a systematic review of the efficacy and safety of Prasugrel in ACS. Method: A systematic review method was used to search for studies meeting the inclusion criteria for analysis. Results: A total of 17 studies on safety and 10 studies on efficacy were included in the review. The compiled research findings also indicate that Prasugrel is relatively safe, with follow-up durations in studies typically ranging from 12 months, with the shortest being 30 days and the longest 10 years. Prasugrel has good safety, with life-threatening bleeding ranging from 0.1% to 2.2% and intracranial hemorrhage from 0.16% to 0.3%. There is no statistically significant difference in bleeding risk being found when compared Prasugrel with Ticagrelor. In terms of efficacy, Prasugrel helps reduce major adverse cardiovascular events (MACE) from 1% to 11.1%, and cardiovascular mortality from 0.6% to 3%. Conclusion: The evidence suggests that Prasugrel reduces the risks of cardiovascular events and shows its clinical benefits when compared with other P2Y12 receptor inhibitors.

References
[1]
WHO. Cardiovascular diseases (CVDs). Accessed June 13, 2024. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Google Scholar
[2]
Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)*. Am J Cardiol. 2002;90(4):358-363. doi:10.1016/S0002-9149(02)02489-X Google Scholar
[3]
Pinaire J, Azé J, Bringay S, Cayla G, Landais P. Hospital burden of coronary artery disease: Trends of myocardial infarction and/or percutaneous coronary interventions in France 2009–2014. PLOS ONE. 2019;14(5):e0215649. doi:10.1371/journal.pone.0215649 Google Scholar
[4]
Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study): Acute Cardiac Care: Vol 14 , No 2 - Get Access. Accessed September 24, 2024. https://www.tandfonline.com/doi/full/10.3109/17482941.2012.655296 Google Scholar
[5]
Segev A, Matetzky S, Danenberg H, et al. Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: insights from the 2010 ACSIS and ACSIS-PCI surveys. doi:10.4244/EIJV8I4A73 Google Scholar
[6]
Boer SPM de, Roos-Hesselink JW, Leeuwen MAH van, et al. Excess mortality in women compared to men after PCI in STEMI: An analysis of 11,931 patients during 2000–2009. Int J Cardiol. 2014;176(2):456-463. doi:10.1016/j.ijcard.2014.07.091 Google Scholar
[7]
WHO. Cardiovascular diseases (CVD) in Viet Nam. Accessed March 26, 2024. https://www.who.int/vietnam/health-topics/cardiovascular-diseases Google Scholar
[8]
Nguyen TV, Bui KX, Tran KD, Le D, Nguyen TN. Non-ST elevation acute coronary syndrome in patients aged 80 years or older in Vietnam: An observational study. PLOS ONE. 2020;15(6):e0233272. doi:10.1371/journal.pone.0233272 Google Scholar
[9]
Bộ Y tế. Quyết định 5332/QĐ-BYT 2020 tài liệu chuyên môn Thực hành chẩn đoán điều trị động mạch vành. THƯ VIỆN PHÁP LUẬT. February 19, 2024. Accessed March 11, 2024. https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quyet-dinh-5332-QD-BYT-2020-tai-lieu-chuyen-mon-Thuc-hanh-chan-doan-dieu-tri-dong-mach-vanh-460209.aspx Google Scholar
[10]
Roe MT, Goodman SG, Ohman EM, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013;128(8):823-833. doi:10.1161/CIRCULATIONAHA.113.002303 Google Scholar
[11]
Baker WL, White CM. Role of prasugrel, a novel P2Y (12) receptor antagonist, in the management of acute coronary syndromes. Am J Cardiovasc Drugs. 2009;9(4):213-229. doi:10.2165/1131209-000000000-00000 Google Scholar
[12]
European Public Assessment Report for Efient. European Medicines Agency website. Accessed June 13, 2024. https://www.ema.europa.eu/en/documents/overview/efient-epar-summary-public_en.pdf Google Scholar
[13]
Bộ Y tế. Thông tư 20/2022/TT-BYT danh mục thanh toán thuốc hóa dược được hưởng bảo hiểm y tế mới nhất. THƯ VIỆN PHÁP LUẬT. January 27, 2024. Accessed March 11, 2024. https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Thong-tu-20-2022-TT-BYT-danh-muc-thanh-toan-thuoc-hoa-duoc-duoc-huong-bao-hiem-y-te-548898.aspx Google Scholar
[14]
Higgins J, Thomas J. Cochrane Handbook for Systematic Reviews of Interventions.; 2021. https://training.cochrane.org/handbook/current/chapter-i Google Scholar
[15]
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482 Google Scholar
[16]
Viikilä J, Nieminen T, Tierala I, Laine M. Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2016;16(1):154. doi:10.1186/s12872-016-0333-0 Google Scholar
[17]
Räber L, Klingenberg R, Heg D, et al. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. JACC Cardiovasc Interv. 2015;8(8):1064-1074. doi:10.1016/j.jcin.2015.03.023 Google Scholar
[18]
Bacquelin R, Oger E, Filippi E, et al. Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). Arch Cardiovasc Dis. 2016;109(1):31-38. doi:10.1016/j.acvd.2015.08.005 Google Scholar
[19]
Kaul U, Sethi A, Arambam P, et al. Safety of Prasugrel in Indian patients - multicentric registry of 1000 cases. Indian Heart J. 2014;66(6):598-601. doi:10.1016/j.ihj.2014.11.001 Google Scholar
[20]
Gill K, Servati N, Flahive J, Fraielli K. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. J Cardiovasc Pharmacol Ther. 2021;26(6):625-629. doi:10.1177/10742484211031436 Google Scholar
[21]
Yetgin T, Boersma E, Smits PC, et al. One-year efficacy and safety of routine prasugrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: results of the prospective rijnmond collective cardiology research study. Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found. 2018;26(7-8):393-400. doi:10.1007/s12471-018-1126-0 Google Scholar
[22]
Ruiz-Nodar JM, Esteve-Pastor MA, Rivera-Caravaca JM, et al. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry. Br J Clin Pharmacol. 2020;86(6):1052-1061. doi:10.1111/bcp.14213 Google Scholar
[23]
Chon MK, Jung SM, Lee SY, et al. Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. Circ J Off J Jpn Circ Soc. 2020;84(9):1582-1586. doi:10.1253/circj.CJ-20-0125 Google Scholar
[24]
Jackson LR 2nd, Peterson ED, McCoy LA, et al. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc. 2016;5(10). doi:10.1161/JAHA.116.003824 Google Scholar
[25]
Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381(16):1524-1534. doi:10.1056/NEJMoa1908973 Google Scholar
[26]
Lam ASM, Yan BPY, Lee VWY. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study. Clin Cardiol. 2021;44(8):1072-1079. doi:10.1002/clc.23653 Google Scholar
[27]
Koyabu Y, Abe S, Sakuma M, et al. Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Intern Med Tokyo Jpn. 2019;58(16):2315-2322. doi:10.2169/internalmedicine.2262-18 Google Scholar
[28]
Liu PY, Su CH, Kuo FY, et al. Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy. Cardiovasc Interv Ther. 2022;37(2):269-278. doi:10.1007/s12928-021-00771-w Google Scholar
[29]
Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J Off J Jpn Circ Soc. 2014;78(7):1684-1692. doi:10.1253/circj.cj-13-1482 Google Scholar
[30]
Hagiwara H, Fukuta H, Hashimoto H, et al. A comparison of the safety and effectiveness of prasugrel and clopidogrel in younger population undergoing percutaneous coronary intervention: A retrospective study using a Japanese claims database. J Cardiol. 2021;77(3):285-291. doi:10.1016/j.jjcc.2020.10.001 Google Scholar
[31]
Almendro-Delia M, García-Alcántara Á, de la Torre-Prados MV, et al. Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Results of a “Real World” Multicenter Registry. Rev Espanola Cardiol Engl Ed. 2017;70(11):952-959. doi:10.1016/j.rec.2017.05.003 Google Scholar
[32]
Shahzeb, Ali N, Hadi A, et al. Elective percutaneous coronary interventions-A comparision of efficacy of Clopidogrel and Prasugrel. J Ayub Med Coll Abbottabad JAMC. 2015;27(1):174-177. doi:PMID:%2026182769 Google Scholar
[33]
Daiichi Sankyo. Jasugrel (prasugrel) [package insert]. Drug Administration Vietnam. 2024. Accessed March 1, 2024. https://dichvucong.dav.gov.vn/congbothuoc/index Google Scholar
[34]
2023 ESC Guidelines for the management of acute coronary syndromes. Accessed March 26, 2024. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Coronary-Syndromes-ACS-Guidelines Google Scholar